Literature DB >> 23719057

Benign notochordal cell tumors of the spine: natural history of 8 patients with histologically confirmed lesions.

J Bryan Iorgulescu1, Ilya Laufer, Meera Hameed, Patrick Boland, Yoshiya Yamada, Eric Lis, Mark Bilsky.   

Abstract

BACKGROUND: Notochord-related lesions of the spinal column include benign notochordal cell tumors (BNCTs), ecchordosis physaliphora, both generally considered benign lesions, and chordomas, which represent malignant tumors. The histological similarity of these lesions to the notochord and each other and their strong predilection to the axial skeleton have led to the hypothesis that these lesions represent a continuum of malignant transformation from notochordal remnants, BNCTs, and finally chordomas.
OBJECTIVE: To present a cohort of biopsy-proven BNCTs with a description of radiographic features, histology, and follow-up to help elucidate the optimal management of these lesions.
METHODS: A retrospective chart review identified 13 patients with notochordal rest lesions confirmed by histology. Histologic inclusion criteria included notochordal features without evidence of septation, myxoid matrix, nuclear atypia, or mitotic figures. Tumors exhibiting evidence of cortical expansion or destruction were excluded. The natural history and histological and radiographic features were examined.
RESULTS: Sixteen spinal lesions from 8 patients met the diagnostic criteria for BNCTs, identified on imaging after the patient presented with back pain. Radiographically, all lesions were hypointense on T1-weighted magnetic resonance imaging sequences and hyperintense on T2-weighted and short T1 inversion recovery. The median radiographic follow-up was 21.6 months (range, 8.5-71.2 months). None of the lesions exhibited radiographic or symptomatic progression.
CONCLUSION: Although limited by short follow-up, our series confirms that these lesions may be safely observed without evidence of malignant transformation, which emphasizes the importance of distinction of BNCT from chordoma at diagnosis and the possibility of close follow-up for these lesions instead of aggressive treatment indicated in patients with chordomas.

Entities:  

Mesh:

Year:  2013        PMID: 23719057     DOI: 10.1227/01.neu.0000431476.94783.c6

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Chordoma arising from benign multifocal notochordal tumors.

Authors:  Abdulrehman Arain; Francis John Hornicek; Joseph H Schwab; Ivan Chebib; Timothy A Damron
Journal:  Skeletal Radiol       Date:  2017-08-03       Impact factor: 2.199

2.  Ecchordosis Physaliphora: Evaluation with Precontrast and Contrast-Enhanced Fast Imaging Employing Steady-State Acquisition MR Imaging Based on Proposed New Classification.

Authors:  A Özgür; K Esen; E Kara; E Yencilek; Y Vayisoğlu; T Kara; A Yıldız
Journal:  Clin Neuroradiol       Date:  2014-12-10       Impact factor: 3.649

3.  Benign notochordal cell tumor: a retrospective study of 11 cases with 13 vertebra bodies.

Authors:  Xiaomei Ma; Chunyan Xia; Dong Liu; Huimin Liu; Chenguang Wang; Hongyu Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Do All Notochordal Lesions Require Proton Beam Radiotherapy? A Proposed Reclassification of Ecchordosis Physaliphora as Benign Notochord Cell Tumor.

Authors:  Aïsha Sooltangos; Istvan Bodi; Prajwal Ghimire; Konstantinos Barkas; Sinan Al-Barazi; Nick Thomas; Eleni C Maratos
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-12

Review 5.  Magnetic Resonance Imaging correlates of benign and malignant alterations of the spinal bone marrow.

Authors:  Carlo Masciocchi; Ferdinando Caranci; Enrico Tedeschi; Lorenzo Ugga; Alessandra D'Amico; Serena Schipani; Silvia Bartollino; Claudio Russo; Alessandra Splendiani; Francesco Briganti; Marcello Zappia; Mariarosa A B Melone; Luca Brunese
Journal:  Acta Biomed       Date:  2018-01-19

6.  Diagnosis of benign notochordal cell tumor of the spine: is a biopsy necessary?

Authors:  Satoshi Tateda; Ko Hashimoto; Toshimi Aizawa; Haruo Kanno; Shin Hitachi; Eiji Itoi; Hiroshi Ozawa
Journal:  Clin Case Rep       Date:  2017-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.